Publication

Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study

Du, Y., Sidorenkov, G., Heuvelmans, M. A., Groen, H. J. M., Vermeulen, K. M., Greuter, M. J. W. & de Bock, G. H., 18-Aug-2020, In : European Journal of Cancer. 135, p. 121-129 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Du, Y., Sidorenkov, G., Heuvelmans, M. A., Groen, H. J. M., Vermeulen, K. M., Greuter, M. J. W., & de Bock, G. H. (2020). Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study. European Journal of Cancer, 135, 121-129. https://doi.org/10.1016/j.ejca.2020.05.004

Author

Du, Yihui ; Sidorenkov, Grigory ; Heuvelmans, Marjolein A ; Groen, Harry J M ; Vermeulen, Karin M ; Greuter, Marcel J W ; de Bock, Geertruida H. / Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers : a microsimulation modelling study. In: European Journal of Cancer. 2020 ; Vol. 135. pp. 121-129.

Harvard

Du, Y, Sidorenkov, G, Heuvelmans, MA, Groen, HJM, Vermeulen, KM, Greuter, MJW & de Bock, GH 2020, 'Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study', European Journal of Cancer, vol. 135, pp. 121-129. https://doi.org/10.1016/j.ejca.2020.05.004

Standard

Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers : a microsimulation modelling study. / Du, Yihui; Sidorenkov, Grigory; Heuvelmans, Marjolein A; Groen, Harry J M; Vermeulen, Karin M; Greuter, Marcel J W; de Bock, Geertruida H.

In: European Journal of Cancer, Vol. 135, 18.08.2020, p. 121-129.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Du Y, Sidorenkov G, Heuvelmans MA, Groen HJM, Vermeulen KM, Greuter MJW et al. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study. European Journal of Cancer. 2020 Aug 18;135:121-129. https://doi.org/10.1016/j.ejca.2020.05.004


BibTeX

@article{2a58b43daf80469cbb2bc88761eb8cbe,
title = "Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study",
abstract = "Background: Lung cancer screening with low-dose computed tomography (LDCT) reduces lung cancer mortality. The aim of this study was to evaluate the cost-effectiveness of lung cancer screening with LDCT in a high-risk population. Methods: The study used an adapted microsimulation model in a cohort of Dutch heavy smokers for a lifetime horizon from a health insurance perspective. The main outcomes included average cost-effectiveness ratio (ACER), incremental cost-effectiveness ratio (ICER) and lung cancer mortality reduction. The comparator was no screening. Scenarios with different screening intervals and starting and stopping ages were evaluated for 100,000 male heavy smokers and 100,000 female heavy smokers. A cost-effectiveness threshold of 60 k€ per life year gained (LYG) was assumed acceptable. Results: The evaluated screening scenarios yielded ACERs ranging from 17.7 to 32.4 k€/LYG for men and from 17.8 to 32.1 k€/LYG for women. The lung cancer mortality reduction ranged from 9.3% to 16.8% for men and from 7.8% to 13.7% for women. The optimal screening scenario was annual screening from 55 to 80 years for men and biennial screening from 50 to 80 years for women, with an ICER of 51.6 and 45.8 k€ per LYG compared with its previous efficient alternative, respectively. Compared with no screening, the optimal screening scenario yielded an ICER of 27.6 k€/LYG for men and 21.1 k€/LYG for women. The mortality reduction of lung cancer was 15.9% for men and 10.6% for women. Conclusions: Lung cancer LDCT screening is cost-effective in a high-risk population. The optimal screening scenario is dependent on sex.",
keywords = "Cost-effectiveness, Low-dose computed tomography, Lung neoplasm, Mass screening, Microsimulation model, QUALITY-OF-LIFE, CT, NELSON, POPULATION, NODULES",
author = "Yihui Du and Grigory Sidorenkov and Heuvelmans, {Marjolein A} and Groen, {Harry J M} and Vermeulen, {Karin M} and Greuter, {Marcel J W} and {de Bock}, {Geertruida H}",
note = "Copyright {\textcopyright} 2020 Elsevier Ltd. All rights reserved.",
year = "2020",
month = aug,
day = "18",
doi = "10.1016/j.ejca.2020.05.004",
language = "English",
volume = "135",
pages = "121--129",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER SCI LTD",

}

RIS

TY - JOUR

T1 - Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers

T2 - a microsimulation modelling study

AU - Du, Yihui

AU - Sidorenkov, Grigory

AU - Heuvelmans, Marjolein A

AU - Groen, Harry J M

AU - Vermeulen, Karin M

AU - Greuter, Marcel J W

AU - de Bock, Geertruida H

N1 - Copyright © 2020 Elsevier Ltd. All rights reserved.

PY - 2020/8/18

Y1 - 2020/8/18

N2 - Background: Lung cancer screening with low-dose computed tomography (LDCT) reduces lung cancer mortality. The aim of this study was to evaluate the cost-effectiveness of lung cancer screening with LDCT in a high-risk population. Methods: The study used an adapted microsimulation model in a cohort of Dutch heavy smokers for a lifetime horizon from a health insurance perspective. The main outcomes included average cost-effectiveness ratio (ACER), incremental cost-effectiveness ratio (ICER) and lung cancer mortality reduction. The comparator was no screening. Scenarios with different screening intervals and starting and stopping ages were evaluated for 100,000 male heavy smokers and 100,000 female heavy smokers. A cost-effectiveness threshold of 60 k€ per life year gained (LYG) was assumed acceptable. Results: The evaluated screening scenarios yielded ACERs ranging from 17.7 to 32.4 k€/LYG for men and from 17.8 to 32.1 k€/LYG for women. The lung cancer mortality reduction ranged from 9.3% to 16.8% for men and from 7.8% to 13.7% for women. The optimal screening scenario was annual screening from 55 to 80 years for men and biennial screening from 50 to 80 years for women, with an ICER of 51.6 and 45.8 k€ per LYG compared with its previous efficient alternative, respectively. Compared with no screening, the optimal screening scenario yielded an ICER of 27.6 k€/LYG for men and 21.1 k€/LYG for women. The mortality reduction of lung cancer was 15.9% for men and 10.6% for women. Conclusions: Lung cancer LDCT screening is cost-effective in a high-risk population. The optimal screening scenario is dependent on sex.

AB - Background: Lung cancer screening with low-dose computed tomography (LDCT) reduces lung cancer mortality. The aim of this study was to evaluate the cost-effectiveness of lung cancer screening with LDCT in a high-risk population. Methods: The study used an adapted microsimulation model in a cohort of Dutch heavy smokers for a lifetime horizon from a health insurance perspective. The main outcomes included average cost-effectiveness ratio (ACER), incremental cost-effectiveness ratio (ICER) and lung cancer mortality reduction. The comparator was no screening. Scenarios with different screening intervals and starting and stopping ages were evaluated for 100,000 male heavy smokers and 100,000 female heavy smokers. A cost-effectiveness threshold of 60 k€ per life year gained (LYG) was assumed acceptable. Results: The evaluated screening scenarios yielded ACERs ranging from 17.7 to 32.4 k€/LYG for men and from 17.8 to 32.1 k€/LYG for women. The lung cancer mortality reduction ranged from 9.3% to 16.8% for men and from 7.8% to 13.7% for women. The optimal screening scenario was annual screening from 55 to 80 years for men and biennial screening from 50 to 80 years for women, with an ICER of 51.6 and 45.8 k€ per LYG compared with its previous efficient alternative, respectively. Compared with no screening, the optimal screening scenario yielded an ICER of 27.6 k€/LYG for men and 21.1 k€/LYG for women. The mortality reduction of lung cancer was 15.9% for men and 10.6% for women. Conclusions: Lung cancer LDCT screening is cost-effective in a high-risk population. The optimal screening scenario is dependent on sex.

KW - Cost-effectiveness

KW - Low-dose computed tomography

KW - Lung neoplasm

KW - Mass screening

KW - Microsimulation model

KW - QUALITY-OF-LIFE

KW - CT

KW - NELSON

KW - POPULATION

KW - NODULES

U2 - 10.1016/j.ejca.2020.05.004

DO - 10.1016/j.ejca.2020.05.004

M3 - Article

C2 - 32563896

VL - 135

SP - 121

EP - 129

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -

ID: 128129413